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Background: We have previously reported that higher patient satisfaction (PS) with service quality is associated
with favorable survival outcomes in a variety of cancers. However, we argued that patients with greater satisfaction
might be the ones with better self-rated health (SRH), a recognized predictor of cancer survival. We therefore
investigated whether SRH can supersede patient satisfaction as a predictor of survival in prostate cancer.
Methods: Nine hundred seventeen prostate cancer treated at four Cancer Treatment Centers of America® hospitals
between July 2011 and March 2013. PS was measured on a 7-point scale ranging from “completely dissatisfied” to
“completely satisfied”. SRH was measured on a 7-point scale ranging from “very poor” to “excellent”. Both were
dichotomized into two categories: top box response (7) versus all others (1–6). Patient survival was the primary end
point. Cox regression was used to evaluate the association between PS and survival controlling for covariates.
Results: The response rate for this study was 72 %. Majority of patients (n = 517) had stage II disease. Seven hundred
eighty-seven (85.8 %) patients were “completely satisfied”. Three hundred nineteen (34.8 %) patients had “excellent”
SRH. There was a weak but significant correlation between satisfaction and SRH (Kendall’s tau b = 0.18; p < 0.001). On
univariate analysis, “completely satisfied” patients had a significantly lower risk of mortality (HR = 0.46; 95 % CI: 0.25-0.85;
p = 0.01). Similarly, patients with “excellent” SRH had a significantly lower risk of mortality (HR = 0.25; 95 % CI: 0.11-0.58;
p = 0.001). On multivariate analysis, SRH was found to be a significant predictor of survival (HR = 0.31; 95 % CI: 0.12-0.79;
p = 0.01) while patient satisfaction was not (HR = 0.76; 95 % CI: 0.40-1.5; p = 0.40).
Conclusions: SRH supersedes patient satisfaction with service quality as a predictor of survival in prostate cancer. SRH
should be used as a control variable in analyses involving patient satisfaction as a predictor of clinical cancer outcomes.Background
Patient-reported outcomes such as patient satisfaction
(PS) with service quality and self-rated health (SRH) are
being increasingly used as important endpoints in cancer
along with traditional endpoints of tumor response and
survival. PS is an essential indicator of quality in health
care and provides important information about the extent
to which a patient’s needs and expectations are being met.
It provides data concerning the quality of care and treat-
ment delivered by physicians, paramedical staff and the
hospital as a whole [1]. PS is becoming an increasingly im-
portant tool for providers to demonstrate patient focus
and differentiation in the healthcare community, as well* Correspondence: gupta_digant@yahoo.com
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in an oncology setting is particularly salient where patients
are subjected to increasingly complex treatments, exhaust-
ive follow-ups, and numerous visits to hospital [4].
SRH, on the other hand, is a multidimensional con-
struct that includes physical, social, psychological and
functional domains at the very least. There is general
agreement in the medical and scientific research com-
munity that patients are the best source of information
regarding their health. Consequently, SRH assessment
has become a valuable tool for both clinical practice and
research [5]. SRH provides information about the impact
of the disease and its treatment on multiple patient pa-
rameters that can aid physicians in selecting and man-
aging antineoplastic and supportive therapy [5, 6].is distributed under the terms of the Creative Commons Attribution 4.0
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ing that pretreatment SRH can predict survival in
several different types of cancers independent of the ex-
tent of the disease and other clinical prognostic factors
[7–20]. More recently, we have reported that higher PS
with service quality is associated with favorable survival
outcomes in a variety of cancers including breast, colo-
rectal and non-small cell lung [2, 3, 21]. However, while
discussing our results, we cautioned the readers that
patients with greater satisfaction with service quality
might be the ones with better self-rated SRH, a well-
established prognosticator of cancer survival. Concur-
rently, several recently published studies have indicated
a possible link between SRH and PS in cancer [22–29].
Collectively, the above observations indicate that self-
rated SRH might potentially confound the PS and sur-
vival relationship in cancer. However, to the best of our
knowledge, no studies in the literature have explored
this hypothesis in an oncologic setting. Understanding
the interrelationships between SRH, PS and survival can
have important implications in interpreting the results
of studies that report on these measures.
The goal of this study, which is a sequel to our previ-
ously published research cited above, was to investigate
if SRH is a potential confounder of the relationship
between PS with service quality and survival in patients
with prostate cancer undergoing treatment at a national
network of oncology hospitals.
Methods
Study population
All prostate cancer patients who were seen in consult-
ation at one of four Cancer Treatment Centers of
America® (CTCA) hospitals between July 2011 and
March 2013, who elected to have treatment at CTCA
and who had not responded to a PS questionnaire
within the preceding 60 days of treatment were eligible
for this study. The four CTCA hospitals were CTCA
Eastern, CTCA Midwestern, CTCA Southwestern and
CTCA Western. The final surveyed cohort included a
total of 917 patients. This study was approved by the
Institutional Review Board (IRB) at CTCA. The need
for informed consent was waived by the IRB because
there was no direct patient contact in this study. This
study involved collection of existing data from patient
records in such a manner that subjects cannot be iden-
tified, directly or through identifiers linked to the sub-
jects. Patient records/information was anonymized and
de-identified prior to analysis.
Questionnaire
The PS questionnaire used in this study was first imple-
mented at our institution in August 2006. The instru-
ment was developed based on input obtained frompatient focus groups, and survey dimensions were col-
lated from several existing studies or questionnaires of
oncology patients [30–33]. This PS questionnaire covers
the following dimensions: hospital operations and ser-
vices, physicians and staff, and patient endorsements for
others (friends and associates). The questionnaire was
administered by trained survey associates at each CTCA
hospital during a treating patient’s visit. Eligible patients
were typically contacted while they were waiting for
various appointments. The survey was paper-based and
was completed by the patient and returned during that
same visit at designated locations at each CTCA hos-
pital. The survey was not anonymous because the survey
data were linked with the electronic health records to
create a comprehensive dataset which was anonymized
and de-identified prior to analysis.
The questionnaire included PS items on: team giving
you the information you need to understand your medical
condition, team explaining your treatment options, team
involving you in decision making as much as you preferred,
teams communicating with each other concerning your
medical condition and treatment, care manager’s effective-
ness in helping with your care when you are at home, team
treating you with respect and in a professional manner, the
response/call back from scheduling after you have left a
message, waiting time for appointments and satisfaction
with the treating medical oncologist (patient’s primary
physician). The questionnaire contained one overall PS
item measured using the following question: “considering
everything, how satisfied are you with your overall experi-
ence with the institution?” The questionnaire also con-
tained one overall self-rated health (SRH) item measured
using the following question: “how would you rate your
overall health during the last week?” This questionnaire
has not been validated previously.
Statistical analysis
Patient survival was the primary end point, and was
defined as the time interval between the date a patient
first returned the patient survey and the date of pa-
tient’s death from any cause or the date of last con-
tact/last known to be alive. The overall PS item was
used as the primary independent variable in this study
along with nine individual PS items. All PS items were
measured on a 7-point scale ranging from “completely
dissatisfied” to “completely satisfied.” The overall SRH
item was used as the main study covariate/confounder.
It was measured on a 7-point scale ranging from “very
poor” to “excellent.” Because of skewed data distribu-
tions, both PS and SRH items were dichotomized into
two categories for the purpose of this analysis: top box
response (7) versus all others (1–6). Other control var-
iables investigated for their relationship with survival
were prior treatment history, stage at diagnosis, age
Table 1 Baseline patient characteristics
Variable Categories Number (Percent)
Age at the time of first survey Mean 63
Median 62.3
Range 40.8-89.3




Stage at diagnosis Stage I 127 (13.8)
Stage II 537 (58.6)
Stage III 107 (11.7)
Stage IV 146 (15.9)
Treatment History Newly Diagnosed 616 (67.2)
Previously Treated 301 (32.8)
Gupta et al. Health and Quality of Life Outcomes  (2015) 13:137 Page 3 of 9and CTCA hospital. The prior treatment history variable
categorized patients into those who had received definitive
cancer treatment elsewhere before coming to CTCA and
those who were newly diagnosed at CTCA. The stage at
diagnosis variable was dichotomized into metastatic (stage
IV) and non-metastatic disease (stages I-III). For CTCA
hospital, dummy variables were created with CTCA West-
ern as the reference category.
Univariate Cox proportional hazards models were
used to determine which variables showed individual
prognostic value for survival. Multivariate Cox propor-
tional hazards models were then performed to evaluate
the joint prognostic significance of all variables signifi-
cant on univariate analysis. We used both block entry
method (all variables entered together at the same time
in one block) as well as the forward stepwise method.
Forward stepwise method was used because, as is com-
mon in PS data, many of the individual items are highly
correlated. Stepwise regression avoids the problem of
multicollinearity because two highly correlated attri-
butes will normally not both be entered in the model.
Since ‘overall PS’ is highly correlated with other indi-
vidual PS items, it was not included in multivariate Cox
analyses when other PS items were used, in order to
achieve model stability. Instead, “overall PS” was ana-
lyzed separately after adjusting for clinical and demo-
graphic factors. The effect of individual variables on
patient survival was expressed as hazard ratios (HRs)
with 95 % confidence intervals (CIs).
Cox regression with time-invariant covariates as-
sumes that the ratio of hazards for any two groups re-
mains constant in proportion over time. We checked
this assumption by examining log-minus-log plots for
categorical predictors. For continuous predictors, this
assumption was checked using an extended Cox model
with time-dependent covariates. Potential multicolli-
nearity was assessed in two steps. Large values (>0.70)
of Kendall’s tau b correlation coefficient were used as
an initial screen for pairs of PS measures. Kendall’s tau
b is an appropriate measure of association for categor-
ical variables and is commonly used when both vari-
ables have the same number of categories. As a second
check, the variance inflation factor (VIF) was used with
the final model to verify that multicollinearity was not
significantly influencing model coefficients [34, 35].
All data were analyzed using IBM SPSS version 23.0
(IBM, Armonk, NY, USA). A difference was considered
to be statistically significant if the p value was less than
or equal to 0.05.
Results
Response rate
A total of 1,274 returning prostate cancer patients were
contacted at all four hospitals combined to participate inthe survey between July 2011 and March 2013. However,
only 917 patients responded. As a result, the response
rate for this study was 72 %.
Baseline patient characteristics
Table 1 displays baseline patient characteristics of the
entire study population (N = 917). At the time of this
analysis (May 2015), 57 (6.2 %) patients had expired. A
majority of the patients were newly diagnosed at our in-
stitution and had stage II disease at diagnosis. Table 2
describes the distribution of PS items. Seven hundred
eighty-seven (85.8 %) patients were “completely satisfied”
with the overall service quality they received. The high-
est levels of dissatisfaction were observed for the follow-
ing three individual PS items in terms of percent “not
completely satisfied”: waiting time for appointments
(21 %), the response/call back from scheduling after you
have left a message (17.7 %) and care manager’s effective-
ness in helping with your care when you are at home
(17 %). Three hundred nineteen (35.8 %) patients had
“excellent” SRH.
Correlation analysis
Table 3 displays Kendall’s tau b correlation coefficients
among the PS items and SRH. The correlations among
the PS items were weak to strong (ranging from 0.32 to
0.77) and all were statistically significant at the 0.01
level. The correlations between SRH and PS items were
weak (ranging from 0.10 to 0.20) but statistically signifi-
cant at the 0.01 level.
Univariate analysis - predictors of patient survival
As shown in Table 4, the individual PS items that were
significantly predictive of survival on univariate Cox
regression analysis were: “team giving you the information
Table 2 Distribution of patient satisfaction items
How satisfied are you in the following areas: Completely satisfied
Team giving you the information you need to understand your medical condition (n = 891) 761 (85.4)
Team explaining your treatment options (n = 881) 758 (86)
Team involving you in decision making as much as you preferred (n = 880) 776 (88.2)
Teams communicating with each other concerning your medical condition and treatment (n = 871) 741 (85.1)
Care manager’s effectiveness in helping with your care when you are at home (n = 731) 607 (83)
Team treating you with respect and in a professional manner (n = 884) 840 (95)
The response/call back from scheduling after you have left a message (n = 855) 704 (82.3)
Waiting time for appointments (n = 887) 701 (79)
Treating medical oncologist (n = 817) 736 (90.1)
• Items were dichotomized into two groups of “completely satisfied (7)” and “not completely satisfied (1–6)”
• Some sample sizes are less than 917 because of missing responses
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explaining your treatment options”, “team involving you in
decision making as much as you preferred”, “teams com-
municating with each other concerning your medical con-
dition and treatment”, “team treating you with respect
and in a professional manner”, and “waiting time for ap-
pointments”. In addition, the overall PS item was also sig-
nificantly predictive of survival. Among the patient
characteristics, SRH, prior treatment history, stage at diag-
nosis and age were significant predictors of survival.
Multivariate analysis - predictors of patient survival
Before proceeding with multivariate analysis, we checked
the bivariate Kendall’s tau b correlation among the PS
items in order to screen for observable multicollinearity.
“Team explaining your treatment options” was highly
correlated with two other PS items: “team giving you the
information you need to understand your medical condi-
tion” (tau b = 0.76; p < 0.001) and “team involving you in
decision making as much as you preferred” (tau b = 0.77;
p < 0.001). As a result, “team explaining your treatment
options” was not considered further in multivariate ana-
lysis. We also found a weak but significant correlation
between overall PS and SRH (tau b = 0.18; p < 0.001).
Table 5 displays the results of the multivariate Cox re-
gression for the following two models: “Model I” investi-
gated five individual PS items controlling for SRH, stage
at diagnosis, prior treatment history and age. “Model II”
investigated the overall PS item controlling for SRH,
stage at diagnosis, prior treatment history and age. In
“Model I,” no PS item reached statistical significance
whereas stage at diagnosis, treatment history, age and
SRH were all found to be statistically significant. In
“Model II,” the item pertaining to overall PS lost its stat-
istical significance whereas SRH, stage at diagnosis,
treatment history and age retained their statistical sig-
nificance from univariate analysis. Figure 1 displays the
adjusted survival curves for the two categories of SRH
after controlling for overall PS, stage at diagnosis,treatment history and age. The SRH curves were signifi-
cantly different from each other (p = 0.01). Figure 2 dis-
plays the adjusted survival curves for the two categories
of overall PS after controlling for SRH, stage at diagno-
sis, treatment history and age. The PS curves were not
significantly different from each other (p = 0.40).
The results of both models were confirmed using the
forward stepwise approach. VIF values for the PS mea-
sures ranged from 1.2 to 2.3, none of which indicates a
significant problem with multicollinearity [34, 35]. There
was no evidence of non-proportional hazards in the
multivariate models presented.
Discussion
PS with service quality can at times be affected by resist-
ance to the lifestyle changes that a cancer diagnosis and
treatment entails and might not necessarily be a reflec-
tion of the patients’ perceptions of care with their
healthcare providers. As a result, it becomes imperative
to understand the relationship between PS and SRH,
particularly within the context of cancer survival. In this
study, we investigated the association between PS with
service quality and survival after controlling for the
effects of SRH in prostate cancer patients treated at a
national oncology hospital network.
The univariate findings of this study suggest that
patients completely satisfied with their service quality
experience better survival outcomes compared to those
who are not. However, after controlling for the effects of
SRH in multivariate models, the relationship between PS
and survival was rendered non-significant. On the other
hand, SRH was found to be an independent predictor of
survival in multivariate analysis after controlling for PS.
This finding coupled with the observation that PS and
SRH were significantly correlated (albeit weakly) sug-
gests that SRH is a potential confounder of the relation-
ship between PS with service quality and survival in
prostate cancer. As a result, we propose that future stud-
ies involved in the collection and analysis of PS data
Table 3 Correlation analysis of patient satisfaction items with self-rated health



















Medical oncologist .57 1.0
Information .52 .47 1.0
Explaining
treatment
.50 .49 .76 1.0
Involvement in
decisions
.49 .43 .67 .77 1.0
Team
communication
.53 .44 .73 .69 .70 1.0
Help with home
care
.44 .40 .57 .64 .58 .66 1.0
Respectful
treatment
.40 .36 .48 .48 .55 .50 .50 1.0
Scheduling .41 .36 .40 .40 .37 .40 .46 .33 1.0
Waiting time .41 .36 .38 .37 .36 .38 .45 .32 .62 1.0
Overall health .18 .19 .17 .19 .18 .14 .19 .10 .17 .20 1.0



















Table 4 Univariate cox regression analysis
Variable HR 95 % CI P-value
Individual PS items
Team giving you the information you need to understand your medical condition 0.45 0.24 to 0.82 0.009*
Team explaining your treatment options 0.40 0.22 to 0.73 0.003*
Team involving you in decision making as much as you preferred 0.31 0.17 to 0.56 <0.001*
Teams communicating with each other concerning your medical condition and treatment 0.37 0.21 to 0.66 0.001*
Care manager’s effectiveness in helping with your care when you are at home 0.55 0.29 to 1.06 0.08
Team treating you with respect and in a professional manner 0.39 0.17 to 0.92 0.03*
The response/call back from scheduling after you have left a message 0.75 0.37 to 1.5 0.41
Waiting time for appointments 0.51 0.29 to 0.90 0.02*
Treating medical oncologist 1.7 0.52 to 5.3 0.40
Overall PS item
Overall patient satisfaction with the institution 0.46 0.25 to 0.85 0.01*
Patient characteristics
Overall self-rated health (“not excellent” as referent) 0.25 0.11 to 0.58 0.001*
Treatment History (newly diagnosed as referent) 3.7 2.2 to 6.4 <0.001*
Stage at diagnosis (stages I-III as referent) 3.1 1.8 to 5.3 <0.001*
Age at first survey (used as a continuous variable) 1.1 1.02 to 1.1 0.002*
CTCA Hospital (overall effect) 0.06
Midwestern versus Western 2.1 0.49 to 9.0 0.32
Southwestern versus Western 4.2 0.98 to 18.2 0.06
Eastern versus Western 4.5 1.0 to 19.5 0.05*
• *P <0.05
• Individual and overall PS iems were dichotomized into two categories: “completely satisfied” (7) and “not completely satisfied” (1–6). “Not completely satisfied”
was the referent group
• Self-rated health was dichotomized into two categories: “excellent” (7) and “not excellent” (1–6). “Not excellent” was the referent group
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meaningful interpretation of their results. SRH should
be an important stratification variable to consider when
analyzing the data on PS in oncology.
Patients know better than anyone how they are feeling,
and when patients report feeling less than in excellent
health, this can be a sign that their disease is not
responding well to treatment, or its associated side ef-
fects. Without clinical measures of treatment efficacy,
these results also suggest that SRH is a reasonable proxy,
since it has an independent effect on survival of the
same order of magnitude as disease stage. This finding
of a positive relationship between SRH and survival in
oncology has been extensively reported in the literature
over the last two decades [7–20]. Similarly, the finding
of a positive relationship between PS and SRH has been
recently reported in a few studies [22–29]. However,
what is unique about this study is the fact that we have
systematically and concurrently analyzed these inter-
relationships in an oncology setting using survival as the
primary endpoint.
Patient satisfaction, which is often assessed by heath
care organizations, may be viewed as a useful, if imprecise,indicator of prognosis in prostate cancer patients, whether
that association be due to improved general health, more
positive emotions, or a combination of these. Although
clinical indicators of prognosis are primary, these findings
suggest that health care providers pay close attention to
those patients who are less than completely satisfied
during treatment. Doing so and alleviating any readily
remedied causes of dissatisfaction may improve patient
commitment to treatment protocols and secondary factors
such as adequate nutrition.
There are some limitations of this study worth ac-
knowledging. Our patient population was limited to
only those patients who spoke English, so this study
sample is, therefore, not broadly representative of pros-
tate patients in general. Further, our study, which is ex-
ploratory by nature, used a non-validated questionnaire
measuring PS and SRH. We were not able to control
for patient co-morbidities due to lack of relevant data.
Given that co-morbidities are significantly associated with
patient survival, lack of adjustment for them leaves room
for residual confounding in our analysis. Finally, we could
not perform a comparison of baseline characteristics
between responders and non-responders since we did not
Table 5 Multivariate cox regression analysis
Variable HR 95 % CI P-value
Model I: individual PS items
Team giving you the information you need to understand your medical condition 0.87 0.30 to 2.5 0.80
Team involving you in decision making as much as you preferred 0.42 0.17 to 1.0 0.06
Teams communicating with each other concerning your medical condition and treatment 1.1 0.38 to 3.5 0.80
Team treating you with respect and in a professional manner 1.4 0.49 to 4.2 0.51
Waiting time for appointments 0.71 0.36 to 1.4 0.34
Overall self-rated health (“not excellent” as referent) 0.30 0.11 to 0.86 0.03*
Treatment History (newly diagnosed as referent) 2.9 1.6 to 5.2 <0.001*
Stage at diagnosis (stages I-III as referent) 3.4 1.8 to 6.2 <0.001*
Age at first survey (used as a continuous variable) 1.1 1.02 to 1.1 0.001*
Model II: overall PS item
Overall patient satisfaction with the institution 0.76 0.40 to 1.5 0.40
Overall self-rated health (“not excellent” as referent) 0.31 0.12 to 0.79 0.01*
Treatment History (newly diagnosed as referent) 2.8 1.6 to 5.0 <0.001*
Stage at diagnosis (stages I-III as referent) 3.5 1.9 to 6.3 <0.001*
Age at first survey (used as a continuous variable) 1.1 1.02 to 1.1 0.002*
• *P <0.05
• Individual and overall PS items were dichotomized into two categories: “completely satisfied” (7) and “not completely satisfied” (1–6). “Not completely satisfied”
was the referent group
• Self-rated health was dichotomized into two categories: “excellent” (7) and “not excellent” (1–6). “Not excellent” was the referent group
• Model I investigates the individual PS items controlling for self-rated health, treatment history, stage at diagnosis and age
• Model II investigates the overall PS item controlling for self-rated health, treatment history, stage at diagnosis and age
Fig. 1 Adjusted survival curve for SRH. It displays the adjusted survival curves for the two categories of SRH after controlling for overall PS, stage
at diagnosis, treatment history and age. The SRH curves were significantly different from each other (p = 0.01)
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Fig. 2 Adjusted survival curve for overall PS. It displays the adjusted survival curves for the two categories of overall PS after controlling for SRH,
stage at diagnosis, treatment history and age. The PS curves were not significantly different from each other (p = 0.40)
Gupta et al. Health and Quality of Life Outcomes  (2015) 13:137 Page 8 of 9have any information available on non-responders. Since
responders can differ from non-responders with regard to
certain baseline demographic and clinical characteristics,
the possibility of selection bias affecting our results cannot
be ruled out.
The strengths of our study include a large sample size,
a good response rate of 72 %, the fact that we measured
PS and SRH as close to the time service was delivered as
possible, and the fact that we used overall patient
survival (the most objective and most commonly used
health outcome measure in oncology) as our dependent
variable. To the best of our knowledge, this study is the
first in the health care literature to report on the associ-
ation between PS with service quality and survival con-
trolling for the confounding effects of SRH in a large
sample of prostate patients.Conclusion
In conclusion, SRH confounds the PS-survival relation-
ship in prostate cancer. SRH should be used as a control
variable in analyses involving PS as a predictor of clinical
cancer outcomes.
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